[Clinical efficiency of candesatran depends on angiotension II receptor, type 1 gene polymorphism].
Frequency of A and C alleles of the polymorphic gene (A1166C) of first type angiotension II receptor in healthy men of Poltava region was 68% and 32% accordingly, the AA, AC and CC genotypes made up 51%,34% and 15% correspondingly. The patients with essential hypertension had the following figures: 44% and 56%; 23%, 52% and 25% accordingly. The presence of C allele has been established to lead to more severe course and an early development of essential hypertension. Candesatran monoterapy is more effective for treatment patients having C allele.